CYTO — Cytophage Technologies Cashflow Statement
0.000.00%
Last trade - 00:00- CA$2.83m
- CA$4.60m
Annual cashflow statement for Cytophage Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -3.24 | -3.68 | -4.64 |
| Depreciation | |||
| Non-Cash Items | 0.054 | 0.45 | 0.832 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -0.147 | -0.075 | 0.432 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | -3.03 | -2.94 | -2.86 |
| Capital Expenditures | -0.333 | -0.381 | -0.162 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | — | -2.46 |
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -0.333 | -0.381 | -2.62 |
| Financing Cash Flow Items | -0.091 | 0 | 2.45 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 6.58 | 0.728 | 3.26 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 3.22 | -2.6 | -2.21 |